Last updated: August 1, 2026
Nadolol and bendroflumethiazide is an established fixed-dose antihypertensive combination historically marketed in the United States as Corzide. The product combines the beta blocker nadolol with the thiazide diuretic bendroflumethiazide. No active late-stage clinical development program, meaningful current branded-market activity, or identifiable active U.S. patent barrier supports a commercial relaunch based solely on the legacy combination. Future demand is likely to remain limited to generic, institutional, or physician-directed use.
What is nadolol and bendroflumethiazide used for?
Nadolol and bendroflumethiazide is indicated for hypertension when treatment with a beta blocker and a diuretic is clinically appropriate. Nadolol reduces cardiac rate and contractility through beta-adrenergic blockade. Bendroflumethiazide promotes sodium and water excretion, reducing plasma volume and blood pressure.
The historical fixed-dose product was supplied in two principal strengths:
| Product |
Nadolol strength |
Bendroflumethiazide strength |
Historical use |
| Corzide 40/5 |
40 mg |
5 mg |
Hypertension |
| Corzide 80/5 |
80 mg |
5 mg |
Hypertension |
The combination is not a first-line choice in most contemporary hypertension guidelines. Current treatment algorithms generally prioritize thiazide-like diuretics, ACE inhibitors, angiotensin receptor blockers, and calcium-channel blockers. Beta blockers are used selectively, including in patients with ischemic heart disease, arrhythmia, heart failure indications, or other compelling cardiovascular requirements (U.S. Department of Veterans Affairs, 2020).
What is the FDA regulatory status of nadolol and bendroflumethiazide?
The product has a legacy FDA approval history rather than an active innovation program. Corzide was approved under an older U.S. new drug application for the fixed-dose combination. Public drug databases identify the product as discontinued or commercially unavailable in the United States, although individual active ingredients and alternative generic antihypertensive combinations remain available.
FDA regulatory position
| Regulatory issue |
Current assessment |
| Original product |
Corzide fixed-dose tablets |
| Active ingredients |
Nadolol and bendroflumethiazide |
| FDA pathway |
Legacy NDA product |
| Current U.S. commercial status |
Discontinued or not broadly marketed |
| Approved indication |
Hypertension |
| Current development status |
No visible active clinical development program |
| Biosimilar pathway |
Not applicable |
| Generic pathway |
Conventional ANDA pathway, if a sponsor markets an equivalent product |
| Pediatric exclusivity |
No current evidence of a relevant pediatric exclusivity period |
| Orphan-drug exclusivity |
Not applicable |
FDA drug-label databases continue to provide historical prescribing information for nadolol/bendroflumethiazide products. FDA defines a discontinued product as one that is no longer marketed, while discontinuation does not necessarily mean the FDA withdrew approval for safety or efficacy reasons (U.S. Food and Drug Administration, n.d.-a).
Are there active clinical trials for nadolol and bendroflumethiazide?
No active, late-stage clinical trial program is evident for the fixed-dose combination. The clinical development record is consistent with an old, approved antihypertensive product rather than a drug undergoing modern efficacy, safety, formulation, or label-expansion studies.
Clinical-trial assessment
| Trial category |
Current assessment |
| Phase 1 studies |
No active program identified |
| Phase 2 studies |
No active program identified |
| Phase 3 hypertension trials |
No active program identified |
| Cardiovascular outcomes trials |
No active program identified for the combination |
| Combination-product reformulation studies |
No active program identified |
| Pediatric trials |
No active program identified |
| Postmarketing commitment |
No current high-profile commitment identified |
| Biosimilar studies |
Not applicable |
Historical clinical evidence for the product predates the current ClinicalTrials.gov registration framework. Existing evidence supports the pharmacologic activity of the component drugs, but it does not indicate a current development opportunity comparable with newer fixed-dose antihypertensive combinations (National Library of Medicine, n.d.).
When does nadolol and bendroflumethiazide lose exclusivity?
The principal exclusivity period has already expired. Nadolol and bendroflumethiazide has been marketed for decades, and any original composition-of-matter, formulation, or regulatory exclusivity would no longer block generic competition.
Patent and exclusivity position
| Protection type |
Assessment |
| Original drug patent |
Expired |
| Fixed-dose combination protection |
Any historical protection would be expired |
| Regulatory exclusivity |
Expired |
| Orange Book patent barrier |
No current blocking patent identified for the legacy combination |
| Patent-term extension |
No commercially relevant remaining term |
| Data exclusivity |
Expired |
| U.S. generic entry barrier |
Primarily commercial and manufacturing-related, not patent-related |
A current Orange Book review should distinguish between an approved product that is no longer marketed and an active listed patent. Discontinued products can remain in FDA historical records, but that record does not create ongoing market exclusivity. FDA’s Orange Book identifies approved drug products and, where applicable, patent and exclusivity information (U.S. Food and Drug Administration, n.d.-b).
What patents protect nadolol and bendroflumethiazide?
No current U.S. patent estate appears to provide meaningful exclusivity for the legacy combination. The likely historical protection covered the original fixed-dose composition and product approval. Those rights have reached the end of their ordinary commercial life.
Formulation patents
The product’s commercial differentiation was based on combining two established active ingredients in a tablet rather than on a novel delivery system. There is no known current U.S. patent position comparable with extended-release technology, transdermal delivery, osmotic delivery, or a protected multiparticulate formulation.
Potential residual IP categories include:
- Manufacturing processes for tablet compression or coating.
- Excipient selection and dissolution control.
- Packaging or stability methods.
- Jurisdiction-specific formulation claims.
- Process know-how that is not publicly disclosed.
These categories would not normally prevent an ANDA sponsor from developing a conventional immediate-release equivalent unless a live patent were identified in the relevant jurisdiction.
Method-of-use patents
No commercially significant active method-of-use patent is evident for the combination. The approved use in hypertension is long established. A new patent would require a differentiated indication, dosing regimen, patient population, or clinical effect supported by patentable disclosure. No such current program is apparent.
What is the Orange Book status of nadolol and bendroflumethiazide?
The Orange Book is relevant for determining whether an approved reference product has listed patents or exclusivity that could affect an ANDA applicant. For this legacy combination, the commercial risk is not a live Orange Book patent dispute. The more important questions are whether an approved reference product remains available for ANDA referencing and whether a current sponsor has maintained commercial supply.
An applicant seeking to market the combination would need to assess:
- Whether an FDA-listed reference product is available for the proposed strengths.
- Whether the reference product is designated as a suitable reference listed drug.
- Whether the proposed product can meet bioequivalence requirements.
- Whether bendroflumethiazide supply is stable and commercially scalable.
- Whether the product is sufficiently attractive to support launch and ongoing distribution.
Which companies are challenging nadolol and bendroflumethiazide?
There is no visible current Paragraph IV litigation campaign around the combination. The product’s age and apparent lack of active patent protection reduce the incentive for a formal patent challenge.
Paragraph IV risk
A Paragraph IV certification is generally used when an ANDA applicant asserts that a listed patent is invalid, unenforceable, or not infringed. That mechanism has limited relevance where:
- The original patents have expired.
- No current Orange Book patent blocks approval.
- The reference product has limited commercial activity.
- Generic entry can proceed through ordinary regulatory and commercial channels.
The absence of visible litigation does not prove that no historical certification occurred. It indicates that the current competitive issue is unlikely to be patent litigation.
What is the market size for nadolol and bendroflumethiazide?
Public market data generally do not report nadolol/bendroflumethiazide as a separate material pharmaceutical market. The combination is too old and commercially narrow for reliable public revenue estimates comparable with major antihypertensive brands.
Market characteristics
| Factor |
Market implication |
| Therapeutic class |
Mature antihypertensive |
| Product age |
Legacy |
| Brand status |
Limited or discontinued |
| Generic competition |
Potentially available, but commercially narrow |
| Prescriber demand |
Low relative to modern combinations |
| Pricing power |
Minimal |
| Reimbursement |
Generic or low-cost formulary positioning |
| Sales transparency |
Limited standalone reporting |
| Growth driver |
Mainly supply restoration or niche substitution |
| Major risk |
Weak demand and low manufacturing economics |
The addressable market is constrained by the availability of separate nadolol and thiazide products, which allow clinicians and pharmacies to adjust doses independently. Fixed-dose combination products are most attractive when they improve adherence, reduce cost, or have strong formulary support. Nadolol/bendroflumethiazide has limited differentiation on those measures.
What generic launch scenarios exist for nadolol and bendroflumethiazide?
A generic launch would most likely follow one of three scenarios.
Scenario 1: Low-volume specialty generic
A manufacturer launches one or both historical strengths for institutional, wholesaler, or pharmacy demand. The strategy requires low-cost production and disciplined inventory management. This is the most plausible scenario if recurring demand exists but remains small.
Scenario 2: Authorized or relaunch product
A company acquires or licenses the legacy product, restores supply, and markets it to physicians or pharmacies familiar with the brand. The commercial return would depend on historical prescription volume and the cost of reactivating manufacturing and distribution.
Scenario 3: No relaunch
Separate nadolol and thiazide therapy continues to replace the fixed-dose product. This is the most likely outcome if the fixed-dose combination cannot support minimum manufacturing scale.
How strong is the patent estate for nadolol and bendroflumethiazide?
The patent estate is weak from a current commercial-exclusivity perspective.
| Patent-estate criterion |
Assessment |
| Composition-of-matter protection |
Expired |
| Fixed-dose combination protection |
Expired or commercially immaterial |
| Method-of-use protection |
No meaningful active barrier identified |
| Formulation protection |
No current barrier identified |
| Manufacturing protection |
Possible trade-secret value, but not blocking IP |
| Litigation leverage |
Low |
| Freedom-to-operate outlook |
Generally favorable for conventional tablets |
| Differentiation potential |
Low without a new formulation or indication |
The main barriers are regulatory execution, active-ingredient sourcing, product economics, and distribution. A new sponsor would need to confirm jurisdiction-specific patent status before investment or launch.
How does nadolol and bendroflumethiazide compare with competing antihypertensive combinations?
The combination is less competitive than newer fixed-dose products that combine an ACE inhibitor, angiotensin receptor blocker, calcium-channel blocker, or thiazide-like diuretic.
| Attribute |
Nadolol/bendroflumethiazide |
Modern antihypertensive combinations |
| Clinical positioning |
Selective or legacy use |
Broad guideline-based use |
| Dose flexibility |
Limited in fixed-dose form |
Often available across several strengths |
| Guideline preference |
Generally secondary |
Frequently preferred first-line combinations |
| Patent protection |
Expired |
Varies by product |
| Generic availability |
Narrow or uncertain |
Broad for many combinations |
| Commercial demand |
Low |
Larger and more predictable |
| Cardiovascular differentiation |
Beta-blocker component may benefit selected patients |
Often stronger population-level positioning |
Nadolol may retain clinical value in selected patients, including those requiring beta blockade. That does not necessarily create demand for the fixed-dose bendroflumethiazide product because the two components can be prescribed separately.
What licensing deals affect nadolol and bendroflumethiazide?
No major current licensing transaction is publicly associated with the combination. The absence of a meaningful patent estate reduces the value of an exclusive license. A transaction would more likely involve:
- Acquisition of a discontinued product dossier.
- Transfer of manufacturing rights.
- Supply of a finished-dose product.
- Purchase of an established generic product line.
- Regional commercialization rights.
A license would need to be structured around supply, regulatory files, trademarks, and distribution rather than patent exclusivity.
What manufacturing and IP barriers exist?
Manufacturing risk is more significant than patent risk. The product requires qualified sources for both active ingredients, validated blending and compression processes, stability data, dissolution testing, and a regulatory filing that supports the intended strengths.
Potential operational barriers include:
- Limited commercial supply of bendroflumethiazide.
- Low batch volumes and unfavorable production economics.
- Difficulty obtaining a suitable reference product.
- Packaging and stability requirements.
- Low pharmacy inventory turnover.
- Need to maintain two strengths despite limited demand.
- International differences in approved strengths and labeling.
A sponsor could reduce risk by developing the products as separate tablets first, but that would not recreate the fixed-dose combination’s regulatory or commercial profile.
What is the projected outlook for nadolol and bendroflumethiazide?
The five-year outlook is stable to declining for the fixed-dose combination, with a low probability of material market expansion.
| Projection period |
Expected market direction |
Main driver |
| Near term |
Flat to declining |
Limited prescribing and generic substitution |
| Medium term |
Declining or niche-stable |
Continued replacement by separate components |
| Upside case |
Small recovery |
Supply restoration or low-cost generic relaunch |
| Downside case |
Further contraction |
Product discontinuation and formulary substitution |
A relaunch could produce short-term revenue if the market has an unmet supply need. It would not create durable pricing power without a new formulation, a differentiated indication, or a protected delivery technology. The base case is a small, mature generic market with limited investment appeal.
Key Takeaways
- Nadolol and bendroflumethiazide is a legacy fixed-dose antihypertensive combination historically marketed as Corzide.
- No active clinical development program is evident for the combination.
- Original patent and regulatory exclusivity have expired.
- No current patent estate appears to create a meaningful U.S. barrier to conventional generic development.
- Paragraph IV litigation and settlement activity are not prominent current market issues.
- FDA status is primarily historical, with limited or discontinued U.S. commercial activity.
- Market data do not support a reliable standalone revenue estimate.
- The main commercial barriers are low demand, supply economics, reference-product availability, and distribution.
- A generic relaunch could support niche revenue but is unlikely to produce substantial growth.
- Separate nadolol and thiazide therapy is the principal competitive alternative.
FAQs about nadolol and bendroflumethiazide
Is Corzide still available in the United States?
Corzide has limited or discontinued U.S. commercial availability. Product status can vary by manufacturer, wholesaler inventory, and FDA reporting category.
Is nadolol and bendroflumethiazide a biologic?
No. It is a conventional small-molecule tablet and is not subject to the biosimilar approval pathway.
Can a company launch a generic without challenging a patent?
Yes. If no unexpired blocking patent is listed or enforceable, an applicant can use the applicable ANDA certification pathway without a Paragraph IV patent challenge.
Does nadolol have stronger commercial demand than the combination product?
Yes. Nadolol as a standalone beta blocker has broader practical use than the fixed-dose nadolol/bendroflumethiazide product because clinicians can adjust the diuretic component independently.
Would a new extended-release version obtain meaningful patent value?
Potentially, but only if the formulation provides a technically differentiated release profile and satisfies patentability, clinical, regulatory, and commercial requirements. A simple reformulation would face substantial validity and obviousness risks.
References
-
National Library of Medicine. (n.d.). ClinicalTrials.gov. https://clinicaltrials.gov/
-
U.S. Department of Veterans Affairs. (2020). VA/DoD clinical practice guideline for the diagnosis and management of hypertension in the primary care setting. https://www.healthquality.va.gov/
-
U.S. Food and Drug Administration. (n.d.-a). Drugs@FDA: FDA-approved drugs. https://www.accessdata.fda.gov/scripts/cder/daf/
-
U.S. Food and Drug Administration. (n.d.-b). Approved drug products with therapeutic equivalence evaluations, Orange Book. https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book
-
DailyMed. (n.d.). Nadolol and bendroflumethiazide prescribing information. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/
